What Is 5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for its effects on cellular metabolism.
NNMT activity is linked to:
NAD⁺ metabolism
methyl donor balance (SAM/SAH)
adipocyte energy handling
Preclinical work associates NNMT inhibition with increased energy expenditure and reduced fat accumulation in model systems. Most data to date is in vitro and animal-based.
Why Dosage Depends on Form
Searches like “5 amino 1mq dosage” often mix very different contexts.
For this compound, exposure depends strongly on route:
Oral (capsules/tablets) → first-pass metabolism, lower bioavailability
Non-oral (e.g., parenteral in experimental settings) → higher systemic exposure per mg
Because of this, reported ranges differ by form.
5-Amino-1MQ Dosage (Research & Experimental Ranges)
Oral Form (Capsules / Tablets)
In practitioner-reported and research-adjacent contexts, commonly discussed ranges are:
50–100 mg per day (lower range)
100–150 mg per day (mid range)
150–200 mg per day (upper commonly referenced range)
These are typically framed as total daily exposure, sometimes divided across the day.
Rationale:
compensates for oral bioavailability
aligns with ranges used in non-clinical, observational contexts
Non-Oral / Parenteral Contexts
In experimental discussions (non-clinical settings), lower total amounts are often referenced due to higher systemic availability:
~10–25 mg per day (lower range)
~25–50 mg per day (commonly referenced range)
Key point:
Because systemic exposure per mg is higher, these ranges are significantly lower than oral amounts.
What Research Actually Shows
Preclinical studies (primarily in rodents) have demonstrated that NNMT inhibition via compounds in this class can:
increase cellular energy expenditure
reduce adiposity
alter methylation-related pathways
Dosing in animal models is typically reported in mg/kg and does not translate directly to human contexts.
This is why most real-world numbers are derived from extrapolation and community practice, not formal clinical dosing guidelines.
Why More Is Not Necessarily Better
5-Amino-1MQ works by interfering with NNMT activity, which is connected to:
NAD⁺ metabolism
methyl donor balance
Excessive inhibition may theoretically affect:
methylation capacity
nicotinamide handling
Because of this, increasing dose does not necessarily produce linear effects.
Formulation and Quality Considerations
With small molecules like 5-Amino-1MQ, consistency depends on:
compound purity
salt/form used
stability in solution (for non-oral use)
manufacturing accuracy
Differences in formulation can significantly affect observed outcomes even at the same nominal dose.
Limitations of Dosage Data
No standardized clinical dosing guidelines
Most data is preclinical
Human data is limited
Real-world ranges are extrapolated
Dosage should therefore be viewed as range-based and context-dependent, not fixed.
Summary of Typical Ranges
Oral (capsules/tablets):
~50–200 mg per day (most commonly 100–150 mg range)
Non-oral / higher bioavailability contexts:
~10–50 mg per day
These are observed ranges, not standardized recommendations.
FAQ
What is the typical 5-Amino-1MQ dosage
Commonly discussed oral ranges fall between 50 and 200 mg per day depending on context.
Why is injectable or non-oral dosing lower
Because systemic exposure is higher per mg, lower total amounts are typically referenced.
Is there a standard clinical dose
No. There are no established clinical dosing guidelines.
Does higher dosing work better
Not necessarily. Effects depend on metabolic pathways, not just total dose.
Disclaimer
This content is provided for informational and educational purposes only and is intended for research discussion.
It does not provide medical advice, treatment recommendations, or instructions for human use.
Any compound affecting metabolic pathways may carry risk depending on context, formulation, and exposure. Interpretation should be based on available research and conducted under appropriate scientific oversight.